Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics Characteristics and Preliminary Effectiveness of VG161 in Subjects with Advanced Primary Liver Cancer

Next Previous
Trial Profile

A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics Characteristics and Preliminary Effectiveness of VG161 in Subjects with Advanced Primary Liver Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VG 161 (Primary)
  • Indications Cholangiocarcinoma; Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Virogin Biotech; Virogin Biotech - China National Biotec Group (JV)

Most Recent Events

  • 13 Sep 2024 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
  • 04 Jun 2024 Results assessing safety and efficacy of VG161 in patients with hepatocellular carcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 17 Jul 2023 According to a Virogen media release, based on the preliminary data from this study company announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of VG161 for patients with advanced unresectable Hepatocellular Carcinoma.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top